Evidence map›Paper›PMID 34680934›Full record

ArticleGenes2021

Using Comorbidity Pattern Analysis to Detect Reliable Methylated Genes in Colorectal Cancer Verified by Stool DNA Test.

Yi-Chiao Cheng, Po-Hsien Wu, Yen-Ju Chen, Cing-Han Yang, Jhen-Li Huang, Yu-Ching Chou, Pi-Kai Chang, Chia-Cheng Wen, Shu-Wen Jao, Hsin-Hui Huang and 2 more

RetractedOpen access · goldAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Yi-Chiao ChengDivision of Colon and Rectal Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.ORCID 0000-0001-8317-1339
Po-Hsien WuDivision of Colon and Rectal Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
Yen-Ju ChenDepartment of Computer Science and Information Engineering, National Taipei University of Technology, Taipei 10608, Taiwan.
Cing-Han YangDepartment of Computer Science and Engineering, National Taiwan Ocean University, Keelung 20224, Taiwan.
Jhen-Li HuangDepartment of Computer Science and Engineering, National Taiwan Ocean University, Keelung 20224, Taiwan.
Yu-Ching ChouSchool of Public Health, National Defense Medical Center, Taipei 11490, Taiwan.ORCID 0000-0003-4823-6541
Pi-Kai ChangDivision of Colon and Rectal Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
Chia-Cheng WenDivision of Colon and Rectal Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
Shu-Wen JaoDivision of Colon and Rectal Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
Hsin-Hui HuangDepartment of Biochemistry and Molecular Cell Biology, School of Medicine, Taipei Medical University, Taipei 11042, Taiwan.
Yi-Hsuan TsaiDepartment of Computer Science and Information Engineering, National Taipei University of Technology, Taipei 10608, Taiwan.
Tun-Wen PaiDepartment of Computer Science and Information Engineering, National Taipei University of Technology, Taipei 10608, Taiwan.ORCID 0000-0002-2869-4169
Tri-Service General Hospital · TWNational Taipei University of Technology · TWNational Taiwan Ocean University · TWNational Defense Medical Center · TWTaipei Medical University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide in 2020. Colonoscopy and the fecal immunochemical test (FIT) are commonly used as CRC screening tests, but both types of tests possess different limitations. Recently, liquid biopsy-based DNA methylation test has become a powerful tool for cancer screening, and the detection of abnormal DNA methylation in stool specimens is considered as an effective approach for CRC screening. The aim of this study was to develop a novel approach in biomarker selection based on integrating primary biomarkers from genome-wide methylation profiles and secondary biomarkers from CRC comorbidity analytics. A total of 125 differential methylated probes (DMPs) were identified as primary biomarkers from 352 genome-wide methylation profiles. Among them, 51 biomarkers, including 48 hypermethylated DMPs and 3 hypomethylated DMPs, were considered as suitable DMP candidates for CRC screening tests. After comparing with commercial kits, three genes (

Indexed as

DNA MethylationAlcohol OxidoreductasesBiomarkers, TumorColorectal NeoplasmsComorbidityHumansMitochondrial ProteinsMolecular Diagnostic TechniquesOccult BloodProtein Phosphatase 2Sensitivity and SpecificitySyndecan-2Alcohol OxidoreductasesBiomarkers, Tumorhydroxyacid-oxoacid transhydrogenaseMitochondrial ProteinsPPP2R5C protein, humanProtein Phosphatase 2SDC2 protein, humanSyndecan-2biomarkerscolorectal cancerDNA methylationelectronic medical recordsstool DNA test

Identifiers

PMID34680934
PMCPMC8535797
OpenAlexW3203301114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.